Introduction
Interleukin-29 (IL-29), a member of the type III interferon (IFN) family, shares structural similarities with type I IFNs and the IL-10 family. Its production is triggered by viral infections, leading to its interaction with a heterodimeric class II cytokine receptor composed of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha. IL-29 exhibits functional similarities to type I IFNs, including antiviral, antiproliferative, and in vivo antitumor activities. While IL-29's actions resemble those of IFNs, it generally displays lower efficacy and its activity is observed in a narrower spectrum of cell lines. Notably, IFN-lambda 1, IFN-lambda 2, and IFN-lambda3 genes are located in close proximity on human chromosome 19. IL-29 uniquely induces the expression of ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells through an IFN-gamma-independent mechanism. Additionally, IL-29 possesses the ability to generate tolerogenic dendritic cells (DCs), potentially counteracting the functions of IFN-beta. Produced in response to viral infection, IL-29 activates both monocytes and macrophages, stimulating the production of a specific set of cytokines. Consequently, it plays a crucial role in the initiation of innate immune responses at the site of viral infection. Importantly, the antiviral and antiproliferative effects of IFN-Lambda 1 are dependent on specific tyrosine residues within the Interferon-Lambda 2 receptor.
Description
Recombinant human IL-29, expressed in E. coli, is a single, non-glycosylated polypeptide chain consisting of 206 amino acids (specifically, amino acids 20-200). It has a molecular weight of 22.7 kDa. The IL-29 protein has a 23 amino acid His-tag fused to its N-terminus and is purified using proprietary chromatographic methods.
Physical Appearance
A clear solution without any color that has been sterilized by filtration.
Formulation
The IL 29 protein solution has a concentration of 1 mg/ml and is formulated in a buffer containing 20 mM Tris-HCl (pH 8.0) and 10% glycerol.
Stability
For optimal storage, refrigerate the complete vial at 4°C if it will be used within 2-4 weeks. For extended storage, freeze the protein at -20°C. To further enhance long-term stability during storage, consider adding a carrier protein such as HSA or BSA (0.1%). It is important to avoid repeated freeze-thaw cycles to maintain protein integrity.
Purity
The purity of the protein is determined to be greater than 85% as assessed by SDS-PAGE analysis.
Synonyms
Interferon lambda-1, IL-29, IL29, IFN-lambda-1, Cytokine
Zcyto21, Interleukin-29.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSHMGPVPT SKPTTTGKGC HIGRFKSLSP QELASFKKAR DALEESLKLK
NWSCSSPVFP GNWDLRLLQV RERPVALEAE LALTLKVLEA AAGPALEDVL DQPLHTLHHI LSQLQACIQP
QPTAGPRPRG RLHHWLHRLQ EAPKKESAGC LEASVTFNLF RLLTRDLKYV ADGNLCLRTS THPEST.
